Peter F. Lebowitz

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 928 citations · Full text

Neuro-oncology, Untreated Brain Metastases, Medicine +7

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante et al. · The Lancet Oncology · 2012 · 534 citations · Full text

Medicine, Melanoma, Pharmacology +9

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

Phase I/ii Study, Mut Braf Melanoma, Immunotherapeutics +20

Critical role of Rho in cell transformation by oncogenic Ras.

George C. Prendergast, Roya Khosravi‐Far, Patricia A. Solski et al. · PubMed · 1995 · 253 citations